Overview

A Single Arm, Tolerability and Safety Phase IV Study of Fulvestrant(Faslodex® ) as 2nd Line and Later Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

Status:
Completed

Trial end date:
2020-09-16

Target enrollment:

Participant gender:

Summary

This single-arm study aims to assess the safety and tolerability profile of Fulvestrant(Faslodex®) as 2nd line and later therapy in postmenopausal women with locally advanced or metastatic breast cancer. The primary objective is to evaluate the adverse events after Fulvestrant (Faslodex®) for about 6 months

Phase:

Phase 4

Details

Lead Sponsor:

AstraZeneca

Treatments:

Estradiol
Fulvestrant